After finishing at $1.15 in the prior trading day, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $1.17, up 1.74%. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 1160686 shares were traded.
Ratios:
Our goal is to gain a better understanding of ACRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.16 and its Current Ratio is at 4.16. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 03, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $22.Evercore ISI initiated its Outperform rating on October 03, 2023, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Powell Andrew Kenneth William bought 6,000 shares for $1.25 per share. The transaction valued at 7,500 led to the insider holds 28,863 shares of the business.
Powell Andrew Kenneth William bought 8,500 shares of ACRS for $10,455 on Mar 01 ’24. The Director now owns 22,863 shares after completing the transaction at $1.23 per share. On Oct 23 ’23, another insider, Monahan Joseph, who serves as the Chief Scientific Officer of the company, sold 6,000 shares for $5.08 each. As a result, the insider received 30,460 and left with 129,724 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 83.69M and an Enterprise Value of -34.99M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.66 while its Price-to-Book (P/B) ratio in mrq is 0.53. Its current Enterprise Value per Revenue stands at -1.12 whereas that against EBITDA is 0.30.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $11.12, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is 1.1977, while the 200-Day Moving Average is calculated to be 5.0283.
Shares Statistics:
The stock has traded on average 2.03M shares per day over the past 3-months and 1.29M shares per day over the last 10 days, according to various share statistics. A total of 70.89M shares are outstanding, with a floating share count of 64.48M. Insiders hold about 9.09% of the company’s shares, while institutions hold 89.20% stake in the company. Shares short for ACRS as of Feb 29, 2024 were 6.1M with a Short Ratio of 3.01, compared to 6.33M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.60% and a Short% of Float of 9.91%.
Earnings Estimates
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$0.29 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.37, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.08 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.32 and -$1.35 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.82, with 7 analysts recommending between -$0.31 and -$1.49.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $7.48M, while the lowest revenue estimate was $2.26M, resulting in an average revenue estimate of $5.58M. In the same quarter a year ago, actual revenue was $31.25M, down -82.10% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $6M in the next fiscal year. The high estimate is $7.8M and the low estimate is $2.26M. The average revenue growth estimate for next year is up 7.50% from the average revenue estimate for this year.
